Skip to main content
Greg Slabodkin on Muck Rack

Greg Slabodkin

Verified
Buffalo
As seen in: Pharma Manufacturing, The Hill, Pittsburgh Post-Gazette, American Banker, EIN News, Buffalo News, Healthcare Dive, CIO Dive, BioSpace, Mondaq, Supply Chain Dive and
Editor in Chief @PharmaMfg #pharmamanufacturing #biopharma #CDMO #pharma #biotech #biomanufacturing #contractmanufacturing
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Greg

Contact Greg, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Senators sponsor bill seeking transparency on foreign control in US drug supply chain

|
By Greg Slabodkin Verified
| Pharma Manufacturing Verified
With America’s drug supply chain reliant on countries such as China, a bipartisan bill introduced in the U.S. Senate is looking to bring greater transparency on the full scope of foreign influence and control of domestic pharmaceutical manufacturing.
Open in Who Shared Issue with article?

J&J’s supply chain restructuring to cost up to $750M, reduce manufacturing footprint

|
By Greg Slabodkin Verified
| Pharma Manufacturing Verified
While Johnson & Johnson is making a $55 billion investment in U.S. manufacturing, research and development, and technology through early 2029, the company is also paring down its pharmaceutical supply chain as part of a restructuring program to gain efficiencies.
Open in Who Shared Issue with article?

Bora Pharmaceuticals, Insilico ink $2.5B AI drug discovery and development deal

|
By Greg Slabodkin Verified
| Pharma Manufacturing Verified
Artificial intelligence (AI) may not yet have achieved the fully integrated end-to-end efficiencies that advocates have been predicting for the biopharmaceutical industry. However, Bora Pharmaceuticals and Insilico Medicine are joining forces in a potential $2.5 billion collaboration that they contend could apply AI and automation-driven approaches across development planning, process optimization, development, and manufacturing.
Open in Who Shared Issue with article?
See all 4,398 licensed articles (4,434 Total)